For me the most concerning aspect of the story is lack of insider ownership. Maybe easier to smile when you have little skin in the game?
Some of the insiders surely would be getting a little greedy if the results are that fantastic so far in oncology and if their confidence is so high. For me it is the biggest part of the story that is missing. I share some of the cynicism but since next to nothing is priced in for oncology or NASH there is still plenty of upside if either one turns out as even a partial win.
canadapiet wrote:OMG!!!
Amazing!
"Ridculously low shareprice" .............., i'm sure he ment to say: "ridiculously low insider ownership"!!!!!
They give no sign or whatsoever that shareprice is ridiculously low, on the contrary!!
First that horrible offer, then "NASH" on hold (searching for a partner after years of waiting for the P3 is putting them in a weak position, certainly after telling that it would be a pitty to "partner" if you are so close with a "mechanism" in such a lucrative market......., their own words!!!!!!), and for now nothing new on the "oncology" front......
But hey, there is still "HOPE" (again, over and over and over again....)
Becoming a sad story
SPCEO1:
Paul gets the biggest applause from me for his comment about the stock price being "ridiculously low" given what TH has going on in cancer. Just for saying that he took the grade on the Weekly Report Card up at least one level! If he does not believe that to be the case, it will be harder for others to believe it.